TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Hims & Hers Health ( (HIMS) ) has issued an announcement.
On November 13, 2025, Hims & Hers Health, Inc. announced a new share repurchase program allowing the company to buy back up to $250 million of its Class A common stock, set to expire in 2028. This initiative follows the completion of a prior repurchase program where the company bought back 1,334,572 shares for $55.5 million between October 1 and November 7, 2025, indicating a strategic move to manage its equity and potentially enhance shareholder value.
The most recent analyst rating on (HIMS) stock is a Hold with a $39.00 price target. To see the full list of analyst forecasts on Hims & Hers Health stock, see the HIMS Stock Forecast page.
Spark’s Take on HIMS Stock
According to Spark, TipRanks’ AI Analyst, HIMS is a Neutral.
Hims & Hers Health’s overall stock score is driven by strong financial performance and positive earnings call guidance. However, technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation. The company’s high leverage and increased G&A costs pose additional risks.
To see Spark’s full report on HIMS stock, click here.
More about Hims & Hers Health
Hims & Hers Health, Inc. operates in the healthcare industry, focusing on providing telehealth services and personalized health and wellness products to consumers.
Average Trading Volume: 28,546,412
Technical Sentiment Signal: Hold
Current Market Cap: $8.42B
Learn more about HIMS stock on TipRanks’ Stock Analysis page.